Why Your Provisional Patent Application May be Worthless: A $107.5 Million Warning

A patent application is not supposed to be a wish list.

It is supposed to teach someone how to make and use the invention.

That difference just helped wipe out a $107.5 million jury verdict in a major pharmaceutical patent case. The case involved sophisticated cancer drugs, expert witnesses, and years of litigation. But the basic lesson applies just as much to an independent inventor filing a provisional patent application for a new tool, consumer product, software system, medical device, or chemical formula.

You do not necessarily need a finished commercial product. You do not always need a working prototype. You certainly do not need to know every possible version of the invention.

However, you need more than a promising goal and a statement that an expert can figure out the details later.

That is where the patents in Wyeth LLC v. AstraZeneca Pharmaceuticals LP ran into trouble.

The practical takeaway: The stronger the patent protection, the more your application should teach and explain. A thin provisional patent application may give you a filing receipt and allow you to say “patent pending,” but that does not mean it will support the patent claims you eventually need nor stand up in court.

What happened in the Wyeth v. AstraZeneca case?

Wyeth and Puma Biotechnology owned patents involving methods of treating certain drug-resistant lung cancers. AstraZeneca sells Tagrisso, a cancer drug that Wyeth accused AstraZeneca of marketing in a way that induced infringement of the patents.

The patent claims generally covered administering a daily “unit dosage” of an irreversible EGFR inhibitor to a patient. In plain English, the claims were not merely directed to discovering that a category of compounds might affect cancer cells. They required giving a patient a predetermined amount intended to produce a therapeutic effect.

A jury initially sided with Wyeth. It found the patent claims were not invalid, found induced infringement, and awarded $107.5 million in damages.

After the trial, however, the district court judge ruled that no reasonable jury could find the claims adequately enabled. This is called judgment as a matter of law, or JMOL. The judge invalidated the asserted claims despite the jury verdict.

On July 9, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling in a precedential decision.

The Federal Circuit did not say the inventors had discovered nothing useful. It did not say that a patent application must contain completed FDA clinical trials. It also did not create a rule requiring a commercial product before filing.

The problem was the gap between what the patents claimed and what the specification actually taught.

What does “enablement” mean in plain English?

Under U.S. patent law, a patent application must describe the invention in enough detail to allow a person skilled in that field to make and use it without undue experimentation.

Some experimentation is allowed. Patent applications are not required to answer every minor question or explain information that is truly routine and well known in the field.

The application cannot, however, hand a skilled person a research assignment and call that an invention.

Think of it like a recipe.

A useful recipe might allow the cook to adjust the seasoning, substitute a similar pan, or cook for an extra few minutes depending on the oven. That is ordinary experimentation.

A recipe that says, “Combine any suitable ingredients in an effective amount and cook them under conditions that produce a delicious cake” does not really teach anyone how to make the cake.

The Supreme Court summarized the rule in a recent enablement case: “The more one claims, the more one must enable.”

That sentence is worth remembering when preparing any patent application, especially a provisional patent application that may later be used to support broad claims.

Why did these patents fail the enablement requirement?

The Federal Circuit identified several related problems.

1. The patents claimed a broad category of compounds

The specification stated that the irreversible EGFR inhibitor could be “any compound” that bound to a particular location on the target protein.

Broad language is attractive because inventors generally want competitors kept as far away as possible. But broad claims come with a price: the application must provide enough teaching to support the breadth being claimed.

The specification identified only three preferred compounds. Even for those three compounds, the application did not provide a working human dosage that practiced the claimed treatment.

2. The application included laboratory data, but no reliable bridge to the claimed treatment

The patents described in vitro testing. “In vitro” generally means testing performed outside a living body, such as in test tubes or cultured cells.

But the patent claims required daily administration of a therapeutically effective unit dosage to a human patient.

The specification did not explain how to translate the laboratory activity into an appropriate daily human dosage. According to the Federal Circuit, the in vitro data alone did not teach the claimed in-patient treatment.

This distinction matters well beyond pharmaceuticals. Testing one isolated component is not always enough if the claims cover an operating system, a complete machine, or a real-world use that introduces new variables.

3. The dosage ranges were extremely broad and largely unexplained

The specification provided general and “projected” dosage ranges. But it did not adequately explain:

  • how those ranges were derived;
  • how to select the correct dose for a particular compound;
  • how the ranges related to the claimed therapeutic result; or
  • how to distinguish workable doses from unworkable ones.

A numerical range can be helpful. A huge range with no meaningful instructions may simply move the unanswered question from one paragraph to another.

For example, telling an inventor to use “between 1 and 1,000 units” is not particularly useful if 1 unit does nothing, 1,000 units destroys the device, and the application does not teach how to find the workable portion.

4. Some disclosed doses were not workable for patients

The trial evidence showed that therapeutically effective levels for at least two of the three identified compounds exceeded the maximum tolerated human dose. For one compound, testimony indicated that the relevant concentration was more than five times what could be administered to patients.

The Federal Circuit did not hold that every patent claim must include a separate “non-toxic” limitation. Instead, the toxicity evidence showed that the disclosed ranges did not provide a reliable roadmap for practicing the claimed daily treatment.

A skilled person would still need significant testing and screening to determine what, if anything, worked.

5. The specification told the skilled person to supply the missing information

The patents essentially asserted that a skilled artisan would know the effective dose for each patient.

Existing knowledge can supplement a patent application. It cannot replace the core teaching that makes the claimed invention work.

That is an important distinction. You do not need to explain what a screw is in a patent application for a new mechanical assembly. But if the location, angle, tension, or sequence of fastening is what makes your assembly work, you probably should not leave that information out and assume a machinist will discover it.

Does this mean you need a prototype or completed testing before filing?

No.

The Federal Circuit specifically recognized that patent applicants may claim treatment methods and dosage ranges without presenting actual clinical data. The court’s objection was not simply, “No clinical trial, no patent.”

The problem was the combination of:

  • very broad claims;
  • broad projected ranges;
  • no actual working dosage for any covered compound;
  • no reliable method for moving from the disclosed laboratory results to the claimed human treatment; and
  • evidence that portions of the disclosed ranges were not workable.

In many technologies, an inventor can prepare an enabling patent application before building a prototype. A mechanical inventor may be able to provide detailed drawings, dimensions, relationships, materials, and operating steps. A software inventor may be able to describe data inputs, processing logic, decision rules, system architecture, outputs, and alternative workflows.

The question is not merely whether the inventor physically built it.

The better question is: Did the inventor provide enough technical information to teach a skilled person how to make and use it?

Why does this matter for a provisional patent application?

This is where the case becomes especially relevant to independent inventors and small businesses.

The two asserted patents traced their priority chain back to two provisional patent applications filed in 2005. The Federal Circuit did not separately decide whether those provisional applications were entitled to support every later claim. The court evaluated the specifications of the issued patents and held the asserted claims lacked enablement.

Still, the case is a strong warning about provisional filings.

A provisional patent application:

  • is not examined by the USPTO;
  • does not require formal patent claims;
  • usually costs less to prepare and file than a nonprovisional application; and
  • can establish an early filing date for subject matter it adequately discloses.

That last phrase is the important one: for subject matter it adequately discloses.

The fact that the USPTO accepted your provisional application and issued a filing receipt does not mean an examiner reviewed it for enablement. It does not mean the document supports every broad claim you may want to pursue later. It only means the filing met the basic requirements to be received as a provisional application.

To receive the benefit of the provisional filing date, the later patent claims generally must be supported by the provisional application in the manner required by 35 U.S.C. § 112(a). In other words, the provisional application should actually teach the invention for which you later claim priority.

You usually cannot solve a thin provisional application by adding the missing technical details a year later and pretending they were present on the original filing date. New information can be added to a later application, but the new material may receive only the later filing date.

Three common provisional patent application problems

The Wyeth case involved cancer treatment, but the same disclosure problems can appear in almost any technology.

Example 1: A consumer product that claims “any sensor”

Suppose an inventor develops a storage container that automatically detects spoiled food. The provisional application says the container may use “any suitable sensor” and alert the user when spoilage is detected.

That sounds broad, but it leaves several important questions unanswered:

  • What is the sensor detecting?
  • Where is it positioned?
  • What readings indicate spoilage?
  • How are temperature and humidity handled?
  • What threshold triggers the alert?
  • Does the system require calibration?

If those details are the actual inventive work, saying “use any sensor” may describe the goal rather than teach the solution.

Example 2: Software that says “AI does it”

Suppose a provisional application describes software that uses artificial intelligence to identify the best sales leads.

That statement alone may not explain much. A stronger disclosure might identify:

  • the data collected;
  • how the data is cleaned or categorized;
  • the features used for ranking;
  • how the model or rules generate a score;
  • what happens when data is missing;
  • how results are displayed; and
  • alternative non-AI or rule-based implementations.

“Use AI to produce the desired answer” can be the software equivalent of telling the skilled person to figure out the invention.

Example 3: A chemical formula with a huge range

Suppose an inventor discovers that adding a particular material reduces corrosion. The provisional lists a concentration range from 0.01% to 80% but does not explain which concentrations work with which metals, temperatures, or fluids.

A broad range may look impressive. If most of it does not work and the application supplies no method for finding the useful portion, the range may create more questions than answers.

A practical enablement checklist for provisional patent applications

Before filing, consider whether the application includes the following:

1. At least one complete version of the invention

Describe a specific embodiment from beginning to end. Identify the parts, steps, ingredients, data flows, or operating conditions needed to make it work.

2. An explanation of how the invention operates

Do not stop at what the invention accomplishes. Explain how it accomplishes that result.

3. The important technical choices

Identify dimensions, materials, ranges, thresholds, formulas, sequences, settings, or relationships that affect performance. Explain why they matter when possible.

4. Drawings that teach, not merely decorate

Use drawings to show connections, relative positions, process flow, components, alternatives, and operation. Label the features consistently and explain them in the text.

5. Reasonable alternatives

Describe substitute materials, different component arrangements, alternate process steps, optional features, and narrower fallback versions.

This can help support broader protection without relying on unsupported phrases such as “any suitable component.”

6. A connection between test results and the claimed use

When you include experiments, simulations, or prototype data, explain how those results relate to the real-world version of the invention.

7. A distinction between tested and predicted results

Be clear about what was actually built or tested and what is reasonably expected to work. Predicted examples can be useful, but they should provide meaningful technical teaching rather than unsupported promises.

8. Known limits and failure conditions

Inventors sometimes avoid discussing problems because they think a patent application should read like advertising.

It should not.

Explaining operating limits, unsuitable combinations, and ways to avoid failure can make the disclosure more useful and credible. It may also show that you actually understand where the invention works.

9. Enough detail to support the claims you hope to pursue

A provisional application does not require claims, but drafting at least some proposed claims can expose missing support.

For each important claim concept, ask: Where does the application teach this?

10. Follow-up filings when the invention materially changes

Many inventions continue developing after the first provisional application. When you add an important feature, discover the correct range, change the architecture, or solve a technical problem, consider whether another provisional application should be filed before public disclosure or commercial activity.

Each filing may have a different effective date for the material it contains, so keep the timeline organized.

Try the “stranger test”

Here is a simple test I like for provisional patent applications:

Give the document to a technically capable stranger in the relevant field.

Could that person make and use the invention without calling you to ask for the missing secret? Could the person do it with ordinary testing and adjustment, or would the person need to begin a new research project?

You do not have to hand your provisional application to an actual stranger before filing. But reading it from that perspective can reveal where the application relies too heavily on information that exists only in the inventor’s head.

Can AI prepare an enabling provisional patent application?

AI can help organize notes, improve wording, create a first outline, identify inconsistent terminology, and suggest questions that need to be answered.

AI cannot safely invent technical details that the inventor never provided.

This creates a particular risk with provisional patent applications. AI can turn a few paragraphs of thin inventor notes into a document that is long, polished, and very official-looking. The result may still lack the details that make the invention work.

A 40-page application is not necessarily better than a 15-page application. Repetition, generic background material, and long lists of possible components do not replace an enabling technical disclosure.

When using AI, ask it to identify missing information rather than allowing it to quietly fill the gaps with assumptions. Then have the inventor verify every important technical statement.

One confusing phrase in the Federal Circuit opinion

The Wyeth appeal also mentioned “provisional rights.” That phrase does not refer to provisional patent applications.

Provisional rights under 35 U.S.C. § 154(d) involve the possibility of obtaining certain damages for activities occurring after a patent application is published but before the patent issues, subject to specific requirements.

The Federal Circuit did not reach that damages issue because it affirmed that the asserted claims were invalid for lack of enablement.

Frequently asked questions

Does a provisional patent application have to satisfy the enablement requirement?

A provisional application is not examined, but it must include a specification meeting the applicable disclosure requirements of 35 U.S.C. § 112(a). Later claims receive the benefit of the provisional filing date only to the extent the provisional adequately supports them.

Does a provisional patent application need formal claims?

No. Formal claims are not required in a provisional application. However, thinking through possible claims can help identify whether the description supports the scope of protection you hope to obtain.

Is a working prototype required?

Usually not. The law generally focuses on whether the application teaches a skilled person how to make and use the invention, not whether the inventor completed a prototype. Some inventions and unpredictable technologies may require more supporting detail or testing than others.

Can I add missing details when I file the nonprovisional application?

You can add new material to a later application, but the added material generally does not magically receive the earlier provisional filing date. That can become critical if a public disclosure, sale, competing filing, or other prior art arose in the meantime.

Are broad claims always a mistake?

No. Broad claims can be extremely valuable. The application should contain enough examples, alternatives, principles, and technical guidance to support that breadth.

Is this case relevant only to pharmaceutical patents?

No. The amount of detail needed varies by technology, and biotechnology and pharmaceutical inventions can be especially unpredictable. But enablement applies to mechanical, electrical, software, chemical, medical, and other inventions as well.

The biggest lesson for independent inventors

A provisional patent application should not merely prove that you had an idea on a particular date.

It should preserve the technical teaching that makes the idea an invention.

The Wyeth patents survived examination, reached a jury, and initially produced a $107.5 million verdict. They still failed when the court compared the breadth of the asserted claims with what the specification actually taught.

That is an expensive reminder that “patent pending” is not the same as “patent protected.”

Before filing, do not ask only:

Does this document describe my idea?

Also ask:

Does this document teach someone how to make and use the invention I eventually want to claim?

That second question may determine whether your early filing date becomes a valuable asset or merely a date printed on a filing receipt.

Sources and further reading

This article provides general educational information and is not legal advice. Patent rights depend on the specific facts, technology, filing history, and applicable law.